This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Chemed Corporation Is Being Investigated On Behalf Of Shareholders

SAN DIEGO and CINCINNATI, May 10, 2013 /PRNewswire/ --  Shareholder rights law firm Robbins Arroyo LLP is investigating whether officers and directors of Chemed Corporation (NYSE: CHE) breached their fiduciary duties to shareholders. Chemed, through its subsidiaries, provides hospice services to patients in the United States.


The U.S. Department of Justice Files False Claims Act Lawsuit Against Chemed

On May 2, 2013, U.S. Department of Justice ("DOJ") announced that it filed a lawsuit against Chemed, and several of its wholly owned hospice subsidiaries, alleging that the company falsely billed Medicaid tens of millions of dollars for crisis care hospice services costing taxpayers tens of millions of dollars.  Crisis care is available to patients with acute medical symptoms requiring immediate short-term care, and is billed at the highest daily rate a hospice can bill Medicare. 

Specifically, the lawsuit alleges that the company submitted false claims for crisis services that were not necessary, not performed, or not performed in accordance with Medicare requirements.  Further, the lawsuit also alleges that Chemed knowingly submitted false hospice care claims to Medicare for patients who were not terminally ill.  The DOJ complaint also claims that Chemed pressured its staff to increase crisis care claims regardless of whether the services were appropriate or actually being provided.  On news of the lawsuit, Chemed stock fell $13.79 per share, or nearly 17%, to close at $68.00 per share.

Robbins Arroyo LLP Investigates Failed Internal Controls by Chemed Officers and Directors

Robbins Arroyo LLP's investigation concerns whether certain of Chemed's officers and directors failed to implement adequate internal controls.  In addition, Robbins Arroyo LLP is investigating whether these fiduciaries issued false and misleading statements regarding (i) the company's financial condition, and (ii) the implementation and maintenance of internal controls to ensure that Chemed complied with the federal laws.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs